Paratek Pharmaceuticals is focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity agains…
Paratek Pharmaceuticals is focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. We initiated a Phase 3 registration study in acute bacterial skin and skin structure infections in June 2015 to determine the efficacy and safety of omadacycline compared to linezolid. A Phase 3 registration study for community acquired bacterial pneumonia with omadacycline compared to moxifloxacin started enrolling in November of 2015.Paratek Pharmaceuticals is focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. We initiated a Phase 3 registration study in acute bacterial skin and skin structure infections in June 2015 to determine the efficacy and safety of omadacycline compared to linezolid. A Phase 3 registration study for community acquired bacterial pneumonia with omadacycline compared to moxifloxacin started enrolling in November of 2015.
Team (1)
Sectors Paratek Pharmaceuticals, Inc. serves:
Life Sciences
Join Axial's Private M&A Platform
Paratek Pharmaceuticals, Inc. connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
